Bone Density Screening and Re-screening in Postmenopausal Women and Older Men by Gourlay, Margaret L. et al.
Bone Density Screening and Re-screening in Postmenopausal 
Women and Older Men
Margaret L. Gourlay1, Robert A. Overman2, and Kristine E. Ensrud3,4
Margaret L. Gourlay: margaret_gourlay@med.unc.edu; Robert A. Overman: overmar@unc.edu; Kristine E. Ensrud: 
ensru001@umn.edu
1Department of Family Medicine, University of North Carolina, Aycock Building; Manning Drive, 
CB #7595, Chapel Hill, NC 27599-7595, USA
2Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, 
University of North Carolina, Kerr Hall, Room 2304, North Carolina, Chapel Hill, NC 27599-7573, 
USA
3Department of Medicine and Division of Epidemiology, General Internal Medicine (111-0), 
University of Minnesota, Minneapolis, MN 55417, USA
4Department of Medicine, VA Medical Center, One Veterans Drive, Minneapolis, MN, USA
Abstract
Clinical practice guidelines universally recommend bone mineral density (BMD) screening to 
identify osteoporosis in women aged 65 years and older. Risk assessment is recommended to 
guide BMD screening in postmenopausal women under age 65. Insufficient data are available to 
inform standard ages to start and stop BMD screening in postmenopausal women. Based on 
longitudinal studies of incident osteoporosis and fracture in postmenopausal women, an initial 
BMD test should be ordered for all women aged 65, and the frequency of re-screening should be 
based on age and BMD T score (more frequent testing for older age and lower T score). Although 
clinical practice guidelines recommend BMD screening according to risk factors for fracture in 
postmenopausal women under age 65, no standard approach to risk assessment exists. Minimal 
evidence is available to guide osteoporosis screening in men, but some experts recommend 
initiation of BMD screening in men at age 70.
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The past decade (2005–2015) has been an active period of progress in research on 
osteoporosis screening. This article reviews epidemiological issues in screening and 
highlights recent data on the use of bone mineral density (BMD) screening to identify 
osteoporosis in postmenopausal women and older men.
Key Components of the BMD Screening Program
The purpose of BMD screening is to identify a pre-symptomatic condition (osteoporosis) 
that can be treated to avoid morbidity and mortality from osteoporotic fractures [1]. The key 
components of a BMD screening program are as follows:
The Screened Population: Well Individuals
To meet the epidemiological criteria for a screened population, individuals who undergo 
BMD screening must be asymptomatic and without a history of fragility fracture (e.g., hip or 
clinical vertebral fracture), not taking pharmacologic treatment to prevent fractures, and 
without an identified secondary cause of osteoporosis [2].
Clinical Outcome: Major Osteoporotic Fracture
Fractures cause pain, immobility or impaired mobility, lost work days, and decreased quality 
of life and are associated with increased outpatient and inpatient costs that are especially 
high for hip fractures [3]. While both low-trauma and high-trauma fractures might be 
reduced by pharmacologic treatment in individuals with osteoporosis by BMD criteria or 
existing vertebral fracture [4], clinical trials have focused on agents to reduce “osteoporotic 
fractures” or “fragility fractures” associated with minimal trauma. No consensus exists 
regarding the specific fracture sites that should be considered “osteoporotic” or classified as 
fragility-related [5, 6]. Also, although lower BMD predicts fracture risk [7], most fractures 
in older adults occur in individuals who do not have osteoporosis by BMD criteria [8, 9]. In 
this article, we focus on the clinical outcome of “major osteoporotic fracture,” defined by 
the World Health Organization (WHO) to include clinical vertebral fractures and fractures at 
the hip, proximal humerus, or wrist [10]. Of these, hip and clinical vertebral fractures are the 
most clinically relevant fracture outcomes because of their associated high morbidity and 
mortality [11].
Target Condition of Screening: Osteoporosis by BMD Criteria
To define an appropriate target condition for BMD screening, the WHO developed 
diagnostic criteria for osteoporosis in 1994 based on the BMD T score (standard deviation 
from young normative BMD mean) at the lumbar spine and two sites at the hip (femoral 
neck and total hip) measured by dual energy x-ray absorptiometry (DXA) [12]. Osteoporosis 
was defined as a T score ≤−2.50 at any of the three sites, osteopenia as lowest T score 
between −2.50 and −1.00 (not inclusive) at any site, and normal BMD as T score ≥−1.00 at 
all sites [12].
The WHO described the T score cut point for osteoporosis as follows [12]:
Gourlay et al. Page 2













“…all cut-off values are somewhat arbitrary, but a measured value of bone mineral 
more than 2.5 standard deviations below the mean for young healthy women at any 
site (spine, hip, mid-radius) identifies 30 % of all postmenopausal women as 
having osteoporosis, more than half of whom will have sustained a prior fracture of 
the proximal femur, spine, distal forearm, proximal humerus or pelvis.”
Despite the arbitrary and secular nature of the cut point, the clinical relevance of the −2.5 T 
score was later substantiated by multiple rigorous randomized, placebo-controlled trials 
demonstrating that treatment of osteoporosis by WHO diagnostic criteria reduced risk of 
clinical vertebral fractures and hip fractures, with less convincing evidence of reduction of 
fractures at other sites [13–18]. The most important working aspects of the WHO diagnostic 
criteria are as follows:
1. The criteria apply to postmenopausal women and have been extrapolated to older 
men. Fracture risk cannot be accurately estimated by T scores measured in 
premenopausal women or young men, and those individuals are not candidates for 
screening and treatment within the general population.
2. While densitometer manufacturers include BMD norms for both women and men, 
the International Osteoporosis Foundation [19] and the International Society for 
Clinical Densitometry [20] recommend that a uniform Caucasian (non-race-
adjusted) female reference database should be used to calculate T scores for men of 
all ethnic groups. Some experts prefer to calculate T scores based on male norms, 
which results in a higher proportion of the male population being diagnosed as 
osteoporotic [21].
Osteoporosis by BMD criteria is still the target condition for screening that is substantiated 
by the highest level of evidence [2]. The efficacy of pharmacologic treatment in patients 
selected on the basis of fracture risk scores calculated with or without BMD has not been 
tested in randomized controlled trials [22]. In 2014, the National Bone Health Alliance 
proposed an alternative definition of “osteoporosis” that included osteoporosis by BMD 
criteria as well as hip fracture and osteopenia-associated vertebral, proximal humerus, pelvis 
or some wrist fractures, or 10-year fracture risk estimations of ≥3 % for hip or 20 % for 
major osteoporotic fracture calculated using the FRAX fracture risk tool [23]. This 
alternative definition cannot be used in studies of screening because it combines the target 
condition for screening (osteoporosis by BMD criteria) with the clinical outcome that 
screening attempts to prevent (fracture). This leads to time-to-disease estimates that are not 
interpretable for the prevention of fracture. Other experts have recommended against 
expansion of the definition of osteoporosis unless further evidence-based research shows 
that the benefits of such an expansion outweigh the harms [24].
Intervention for Screen-Positive Patients: Pharmacologic Treatment to Prevent Fracture
The clinical efficacy of screening depends on treatment efficacy, i.e., a screening program 
can only be successful if available treatments effectively reduce clinically detectable 
disease. If effective treatments are not available, a test with 100 % accuracy is useless. For 
this reason, randomized controlled trials of treatment precede randomized trials of screening.
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In 2002, BMD screening programs were given a Grade C evidence rating (evidence 
substantiates offering or providing this service for selected patients depending on individual 
circumstances) by the US Preventive Services Task Force after data from randomized 
controlled trials demonstrated fragility fracture reduction in individuals with osteoporosis by 
BMD criteria who received pharmacologic treatment [25]. While the WHO’s −2.50 T score 
cut point was in some sense an arbitrary cutoff, it proved to be a clinically relevant threshold 
for primary fracture prevention in subsequent randomized controlled trials of pharmacologic 
treatment. To date, reduction in clinical fracture events has only been demonstrated in RCTs 
in postmenopausal women with osteoporosis by WHO diagnostic criteria or with existing 
radiographic vertebral fractures or history of clinical vertebral fractures or in patients with 
recent hip fracture regardless of their T score level [13–18].
Despite the lack of direct RCT evidence demonstrating that BMD screening reduces 
fractures or mortality, the USPSTF concluded in 2011 that the net benefit of osteoporosis 
screening was at least moderate in women aged 65 and older and in younger 
postmenopausal women with fracture risk at least as high as a 65-year-old white woman 
who has no additional risk factors (grade B evidence) [26]. This approach has not been 
tested prospectively and is problematic because of the low level of accuracy of the USPSTF 
risk assessment approach to identify younger postmenopausal women who later develop 
osteoporosis or major fracture [27, 28] (see “Postmenopausal Women/Age to Start 
Osteoporosis Screening”).
Other Uses of BMD Testing
Osteoporosis screening is one of several uses of BMD testing. BMD testing may also be 
ordered to rule out osteoporosis in patients with secondary causes of BMD loss, for 
treatment monitoring or for surveillance after a major fragility fracture event. In the latter 
cases, patients who undergo BMD testing have a different risk of future fracture than the 
general population and thereby no longer qualify for a “screening” BMD test.
Postmenopausal Women
According to estimates from the National Health and Nutrition Examination Survey 
(NHANES) 2005–2008, the prevalence of osteoporosis at the femoral neck or lumbar spine 
ranges from 6.8 % in women aged 50 to 59 to 34.9 % in women aged 80 and older [29]. 
Among US women aged 65 and older, approximately 25.1 % have osteoporosis (BMD value 
at least 2.5 standard deviation units below the mean) and 52.3 % have low bone mass (BMD 
value between 1.0 and 2.5 standard deviation units below the mean) calculated using BMD 
norms for young non-Hispanic white females, age-adjusted to the 2010 Census Bureau 
estimates [30]. A meta-analysis of data from 12 cohort studies including 29,082 women 
reported that at the age of 65 years, women’s risk ratio for hip fractures increased by 2.88 
(95 % CI 2.31, 3.59) for each SD decrease in BMD, and their risk of osteoporotic fractures 
(including hip, humeral or limb fractures and fractures of the spine, pelvis, ribs, distal 
forearm and forearm, clavicle, scapula or sternum) increased by 1.38 (95 % CI, 1.28, 1.48) 
per SD decrease in BMD [31, 32].
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Age to Start Osteoporosis Screening
No standard age for starting BMD screening is recommended in clinical practice guidelines. 
Epidemiological data suggest that mass osteoporosis screening and treatment in 
postmenopausal women under age 60 is likely to be very inefficient. For example, the 
USPSTF estimated the number needed to screen to prevent one hip fracture would be more 
than 4000 for women aged 50–59 due to low osteoporosis prevalence and low fracture risk 
before age 60 [33]. A 2008 Cochrane review estimated that the number needed to treat 
(NNT) for alendronate to prevent the first hip fracture was nonestimable in postmenopausal 
women aged 50–54 and 943 for women aged 55–59, and the NNT to prevent the first 
vertebral fracture was 1111 for aged 50–54 and 556 for aged 55–59 [34]. A review of the 
cost-effectiveness literature concluded that treatment with bisphosphonates is likely to be 
cost-effective in populations aged 70 and older, but that “the younger the cohorts and the 
fewer risk factors they have, the less cost-effective treatment with a bisphosphonate is” [35].
No data are available on the benefit of osteoporosis treatment beginning at age 50–59 and 
continuing over three or four decades. Because of rapid rates of BMD loss and trabecular 
perforation during the perimenopausal transition, some experts have proposed antiresorptive 
treatment during early menopause [36], However, the long-term benefit of early therapy 
may be limited because of drug washout after discontinuation. Hormone therapy used in the 
early postmenopausal period does not confer fracture protection after discontinuation [37]. 
Similarly, withdrawal of alendronate leads to BMD declines within 2 years [38, 39]. 
Potential harms from early therapy must also be considered. Because younger 
postmenopausal women have lower immediate risk of fragility fractures, they are 
substantially more likely than postmenopausal women aged 60 and older to sustain harms 
that outweigh benefits from early treatment. Harms of screening include knowledge of low 
bone density that causes anxiety despite lack of symptoms [40]. Early treatment may lead to 
prolonged bisphosphonate use, which has been associated with osteonecrosis of the jaw [41, 
42] and atypical femoral fractures [43, 44]. Finally, overtreating younger postmenopausal 
women when their fracture risk is low may leave them with few or no treatment options in 
their early 70s, when hip fractures start to increase exponentially [45]. This could potentially 
decrease the lifetime potential for net treatment benefit.
In the absence of definitive data on the optimal age to start BMD screening, clinical practice 
guidelines recommend consideration of BMD testing in postmenopausal women as young as 
50 years, with risk factor assessment to guide the decision to order testing from age 50 to 64 
[46, 47]. In its 2010 systematic review on osteoporosis screening, the USPSTF assessed 
studies of 21 externally validated clinical risk-assessment tools including 1 to more than 15 
variables [48]. Most of the tools included age, weight or body mass index, and previous 
fracture. Risk tools to predict low BMD (area under the curve [AUC], 0.13 to 0.87) and 
fractures (AUC, 0.48 to 0.89) were evaluated; simple and complex instruments performed 
similarly. No tool demonstrated high AUC estimates in several studies. “Important 
methodological limitations of studies include nonrepresentative samples, cross-sectional 
rather than prospective data collection, inconsistent performance of the reference standard, 
and differences in performance measures across studies” [48]. A 2014 diagnostic accuracy 
analysis found that the Osteoporosis Self-assessment Tool (OST) and the Simple Calculated 
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Osteoporosis Risk Estimate (SCORE) risk assessment tool had fair to poor diagnostic 
accuracy and that the US Preventive Services Task Force risk assessment strategy based on 
a fracture risk score had poor diagnostic accuracy to identify postmenopausal women aged 
50 to 64 with incident osteoporosis by BMD criteria or major osteoporotic fracture over the 
subsequent 10 years [27, 28]. While the principle behind risk assessment to decide a 
screening test has face validity, a two-step process of risk assessment followed by BMD 
screening decision has not been tested prospectively, and there is no consensus regarding 
which risk factors or which risk tools to use for selection of candidates for BMD screening 
[49].
In a study of osteoporosis incidence in postmenopausal women aged 50 to 64 at baseline 
participating in the Women’s Health Initiative [50], tabulations of fracture events (Table 1) 
during study follow-up suggested that the lowest T scores within the osteopenia range (T 
score −2.49 to −2.00) were relatively infrequent but occurred across all age ranges of 
younger postmenopausal women. Development of osteoporosis by BMD criteria over 11 
years of follow-up was rare in those who had baseline T scores >−1.50. The longitudinal 
results for this study (Fig. 1) also indicated that younger postmenopausal women with 
baseline T scores −2.49 to −2.00 transitioned to osteoporosis as rapidly as women aged 67 
and older. These findings suggest that DXA testing has a role for some postmenopausal 
women across the age range of 50 to 64. However, evidence is lacking to inform a standard 
approach to selection of the best candidates for BMD screening and optimal timing of 
treatment in this age range.
A 2015 analysis documented a decrease in the BMD testing rate in commercially insured 
postmenopausal women aged 50 to 64 between 2006 and 2012, during a time period when 
Medicare reimbursement for DXA BMD testing declined significantly [51]. An estimated 
667,982 DXA scans were performed for younger postmenopausal women in 2012, 
compared to an estimated 2,338,240 DXA tests performed in physician offices and hospitals 
for Medicare beneficiaries in 2009 [51, 52].
Osteoporosis Screening Intervals
Decisions regarding bone density screening intervals were initially based on machine 
precision specifications, i.e., the magnitude of the change in BMD that indicates real 
biological change, called the least significant change (LSC) [53]. A 2007 prospective 
observational study suggested that a second DXA BMD test up to 8 years after the first 
provided little additional fracture prediction in women aged 65 years and older [54]. A 2009 
population-based study including 1008 women and 750 men aged 60 years and older at 
baseline estimated the time to development of osteoporosis or incident fragility fracture [55]. 
This study contributed important information regarding fracture risk stratification according 
to age and BMD T score; however, results were difficult to interpret with respect to 
osteoporosis screening because the pre-symptomatic condition of osteoporosis was 
combined with fragility fractures in the outcome measure.
A 2012 longitudinal study of 4957 women aged 67 and older at baseline tested a BMD 
screening interval defined as the estimated time for 10 % of women to transition from 
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normal BMD or osteopenia to osteoporosis. Important aspects of the study with respect to 
clinical implementation included its large size, 15 years of concurrent imaging and fracture 
follow-up, and methodology that treated pharmacologic treatment and incident hip and spine 
fracture as competing risks rather than censoring criteria. The same authors documented 
time-to-fracture estimates according to baseline age groups of postmenopausal women aged 
50 to 64 in an effort to separate age groups at lower and higher risk of major osteoporotic 
fracture [50].
A comparison of the cumulative incidence of osteoporosis in women aged 67 and older 
participating in the Study of Osteoporotic Fractures (SOF) vs. women aged 50 to 64 
participating in the Women’s Health Initiative (WHI) from the latter two analyses is shown 
in Fig. 1 [50, 56••]. Figure 1 demonstrates that postmenopausal women aged 50 and older 
with baseline T scores between −2.49 and −2.00 may have a rapid transition to osteoporosis. 
Conversely, postmenopausal women with baseline T scores >−1.50 transition to 
osteoporosis much more slowly. For postmenopausal women aged 50 to 64 who undergo 
BMD testing and have baseline T scores >−1.50, the transition to osteoporosis is so slow 
that clinicians might consider deferring the next DXA test to age 65, the age at which 
routine BMD screening is recommended for all women.
While time-to-osteoporosis estimates are helpful, the timing of screening intervals is still a 
subjective decision in primary care practice. Results from the cited studies are only relevant 
for the screened population of well individuals, not patients with pre-existing fracture, 
treatment, or secondary causes of osteoporosis. The plots in Fig. 1 use a 10 % incidence 
threshold as the metric, i.e., the estimated time for 10 % of the T score group or age group to 
develop osteoporosis. A lower or higher threshold might be considered according to the 
patient’s baseline risk factors for fracture or because of the patient’s past history.
Age to Stop Osteoporosis Screening
An age to stop or decrease use of BMD testing has not been examined, and policy 
statements do not recommend cessation of screening at a specific age. In women aged 70 to 
80 years at baseline, osteoporosis treatment is effective and mass BMD screening has been 
assessed as more cost-effective than no screening or screening only in women with at least 
one risk factor for fracture [13, 57–60]. Women aged 80 and older are less well studied 
because they are represented in smaller numbers in cohort studies of BMD and fracture. 
With increasing age, the rate of non-fracture death greatly outweighs fracture-related deaths, 
making BMD screening less likely to be beneficial.
Older Men
According to estimates from the NHANES 2005–2008 [29], the prevalence of osteoporosis 
at the femoral neck or lumbar spine ranges from 3.4 % in men aged 50 to 59 to 10.9 % in 
men aged 80 and older [29]. Among US men aged 65 and older, approximately 5.7 % have 
osteoporosis (BMD value at least 2.5 standard deviation units below the mean) and 44.2 % 
have low bone mass (BMD value between 1.0 and 2.5 standard deviation units below the 
mean) calculated using BMD norms for young non-Hispanic white females, age-adjusted to 
the 2010 Census Bureau estimates [30]. A meta-analysis of data from 12 cohort studies 
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including 9891 men reported that at the age of 65 years, men’s risk ratio for hip fractures 
increased by 2.94 (95 % CI, 2.02, 4.27) for each SD decrease in BMD, and their risk of 
osteoporotic fractures (including hip, humeral or limb fractures and fractures of the spine, 
pelvis, ribs, distal forearm and forearm, clavicle, scapula or sternum) increased by 1.41 (95 
% CI, 1.33, 1.51) per SD decrease in BMD [31, 32].
Osteoporosis and Fracture Risk in Men
A 1998 prospective study of a Dutch cohort of 7046 individuals (2778 men) aged 55 years 
and older suggested that the risk of hip fracture in men and women is similar at the same 
femoral neck absolute bone density level [61], but a 2006 analysis found that men aged 65 
and older had a lower risk of fracture at every T score of hip BMD compared to same-aged 
women [62]. On average, men have higher BMD than age-matched women throughout life, 
and their rate of BMD loss in older age is slower than that for women [63]. As a result, 
fewer men develop osteoporosis, and fragility fractures occur less often in men than in 
women.
Despite lower overall fracture incidence, men have greater morbidity and mortality 
associated with hip fractures compared to women. Men are more likely than women to die 
within 1 year after a hip fracture [64]. Almost one third of men with hip fractures have 
subsequent fractures (of any type) during their remaining lifetime [65]. After a hip fracture, 
most new fractures occur in relatively younger men within 5 years, whereas most aged 75 
and older die before experiencing a new fracture [65]. Fractures at typical osteoporotic sites 
are associated with increased mortality across all age groups of women and men, 
particularly in men [66–71].
Evidence for Pharmacologic Treatment Efficacy in Men
Treatment with oral bisphosphonates is effective in reducing risk of incident radiographic 
vertebral fractures in RCTs up to 3 years in length conducted in men aged 30s to 80s, about 
half of whom had existing radiographic vertebral fracture and many of whom had 
osteoporosis by BMD criteria at baseline [72–78]. A 2012 randomized controlled trial of 
older men with osteoporosis treated with zoledronic acid demonstrated significant reduction 
in the primary endpoint of radiographic vertebral fracture [79••]. However, no RCT has 
demonstrated prevention of clinical fractures in men with or without osteoporosis at 
baseline.
The optimal T score cut point for treatment is uncertain for older men, but data from Ensrud 
et al. suggest that older men with T scores ≤−2.50 calculated using BMD norms for young 
white women may be most likely to benefit from pharmacologic treatment to reduce fracture 
[80••].
Lack of a BMD Screening Protocol in Men
No standard BMD screening schedule exists for men, but several subspecialty organizations 
have offered recommendations based on expert opinion. Based on literature reviews by 
expert panels, the National Osteoporosis Foundation [46] and International Society for 
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Clinical Densitometry [81] supported BMD screening in all men aged 70 and older and in 
men aged 50 to 69 with clinical risk factors for fracture. The American College of 
Physicians recommended that osteoporosis risk factors be evaluated in men aged 50 to 69 to 
determine whether DXA testing should be considered [82, 83]. They listed important 
osteoporosis risk factors in men to be age (>70 years), low body weight (body mass index 
<20 to 25 kg/m2), weight loss, physical inactivity, corticosteroid use, androgen deprivation 
therapy, and previous fragility fracture. Studies are needed to compare performance of 
strategies to identify older men who are candidates for osteoporosis screening.
Conclusions
The state of the art of BMD screening has been strengthened by new data published since 
2005. Despite a number of studies of risk assessment tools to select postmenopausal women 
under age 65 for osteoporosis screening, no standard approach has been tested prospectively. 
The very low fracture risk in women aged 50 to 54 argues against frequent screening in this 
age range. Clinical guidelines universally recommend routine BMD screening in women 
aged 65 and older, and recent data suggest that women with baseline T scores ≤−1.50 can 
benefit from more frequent BMD screening than women with T scores >−1.50. Minimal 
evidence exists to inform BMD screening in older men, and studies are needed to compare 
the performance of potential strategies to select individuals for osteoporosis screening in this 
population.
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Cumulative incidence of osteoporosis in postmenopausal women aged 50 to 64 (Women’s 
Health Initiative) vs. 67 years and older (Study of Osteoporotic Fractures). The intersection 
of each plot with the 10 % dotted line threshold is the time for 10 % of women to develop 
osteoporosis by BMD criteria
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Table 1
Proportion of WHI participants aged 50 to 64 at baseline who developed osteoporosis after up to 11 years of 
BMD follow-up [50]
Baseline T score range/agea Total Nb Developed osteoporosis, N (%)a
>−1.50 2554 2 (0.08)
age 50–54 798 1 (0.13)
age 55–59 896 0 (0.00)
age 60–64 860 1 (0.12)
−1.99 to −1.50 712 25 (3.51)
age 50–54 150 5 (3.33)
age 55–59 242 10 (4.13)
age 60–64 320 10 (3.13)
−2.49 to −2.00 466 101 (21.67)
age 50–54 83 24 (28.92)
age 55–59 149 30 (20.13)
age 60–64 234 47 (20.09)
a
BMD T scores at the femoral neck, total hip, or lumbar spine calculated using BMD norms for young white women
b
Tabulations account for the competing risks of incident antifracture treatment, hip, or clinical vertebral fracture or death
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